tadalafil has been researched along with Lupus Erythematosus, Systemic in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Baniotopoulos, P; Dimitroulas, T; Hatzichristodoulou, G; Minopoulou, I; Pyrgidis, N; Sokolakis, I; Tishukov, M | 2 |
| Barberà, JA; Blair, C; Coghlan, JG; Frost, AE; Galiè, N; Ghofrani, HA; Gillies, H; Harris, JHN; Hoeper, MM; Kuwana, M; Langley, J; McLaughlin, VV; Miller, KL; Peacock, AJ; Rubin, LJ; Simonneau, G; Vachiéry, JL | 1 |
2 review(s) available for tadalafil and Lupus Erythematosus, Systemic
| Article | Year |
|---|---|
Treatment of Sexual Dysfunction in Women with Systemic Autoimmune Rheumatic Disorders: A Systematic Review.
Topics: Androgens; Cyclic Nucleotide Phosphodiesterases, Type 5; Female; Humans; Lubricants; Lupus Erythematosus, Systemic; Scleroderma, Systemic; Sexual Dysfunction, Physiological; Tadalafil; Testosterone | 2022 |
Treatment of Sexual Dysfunction in Women with Systemic Autoimmune Rheumatic Disorders: A Systematic Review.
Topics: Androgens; Female; Humans; Lupus Erythematosus, Systemic; Scleroderma, Systemic; Sexual Dysfunction, Physiological; Tadalafil | 2022 |
1 trial(s) available for tadalafil and Lupus Erythematosus, Systemic
| Article | Year |
|---|---|
Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial.
Topics: Adult; Aged; Antihypertensive Agents; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Edema; Female; Humans; Hypertension, Pulmonary; Lupus Erythematosus, Systemic; Male; Middle Aged; Mixed Connective Tissue Disease; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Pyridazines; Scleroderma, Systemic; Tadalafil | 2017 |